Zhiming Shao

Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 60 publications

Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.

Integrative multi-omic analysis identified ERBB2 mutations and senescence-driven immune suppression as dual therapeutic targets in LAR triple-negative breast cancer.

Journal: Cancer biology & medicine

Published: April 13, 2026

Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.

Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors.

Journal: Cancer biology & medicine

Published: March 06, 2026

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

Journal: The New England journal of medicine

Published: December 10, 2025

Comprehensive investigation of the molecular basis of cancer dependencies suggests therapeutic options for breast cancer.

Comprehensive investigation of the molecular basis of cancer dependencies suggests therapeutic options for breast cancer.

Journal: Cancer biology & medicine

Published: October 24, 2025

Correction: Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness.

Correction: Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness.

Journal: Signal transduction and targeted therapy

Published: September 02, 2025

High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.

High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.

Journal: Cancer biology & medicine

Published: July 04, 2025

Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer.

Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer.

Journal: Biomarker research

Published: April 04, 2025

Genomic spectra of lymphovascular invasion in breast cancer.

Genomic spectra of lymphovascular invasion in breast cancer.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: December 26, 2024

PCSK9 V474I germline variant drives breast cancer metastasis.

PCSK9 V474I germline variant drives breast cancer metastasis.

Journal: Life metabolism

Published: December 25, 2024

Pilot Study of Nectin-4-Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.

Pilot Study of Nectin-4-Targeted PET Imaging Agent 68Ga-FZ-NR-1 in Triple-Negative Breast Cancer from Bench to First-in-Human.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: October 21, 2024

Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.

Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.

Journal: Cancer biology & medicine

Published: May 16, 2024

Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.

Neoadjuvant anthracycline followed by toripalimab combined with nab-paclitaxel in patients with early triple-negative breast cancer (NeoTENNIS): a single-arm, phase II study.

Journal: EClinicalMedicine

Published: April 17, 2024

Showing 1-12 of 60

Last Updated: 09/26/2026